Abstract
Cervical cancer is initiated by infection of cervical epithelium with human papillomavirus. Vaccines have been developed, incorporating papillomavirus viral capsids and alum based adjuvants. In extensive clinical trials these vaccines have been shown safe and effective in preventing infection with, and disease caused by, the papillomavirus genotypes they incorporate, in women not already infected. These vaccines have the potential to reduce the global burden of cervical cancer by up to 70%.
MeSH terms
-
Drug-Related Side Effects and Adverse Reactions
-
Epitopes / immunology
-
Female
-
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
-
Human papillomavirus 16 / immunology
-
Human papillomavirus 16 / pathogenicity
-
Human papillomavirus 18 / immunology
-
Human papillomavirus 18 / pathogenicity
-
Humans
-
Mass Vaccination
-
Papillomavirus Infections / immunology
-
Papillomavirus Infections / prevention & control*
-
Papillomavirus Vaccines / administration & dosage*
-
Papillomavirus Vaccines / adverse effects
-
Papillomavirus Vaccines / immunology
-
Precancerous Conditions / immunology
-
Precancerous Conditions / prevention & control
-
Pregnancy
-
Sexually Transmitted Diseases, Viral / immunology
-
Sexually Transmitted Diseases, Viral / prevention & control*
-
Uterine Cervical Dysplasia / immunology
-
Uterine Cervical Dysplasia / prevention & control*
-
Uterine Cervical Neoplasms / immunology
-
Uterine Cervical Neoplasms / prevention & control*
-
Vaccines, Virus-Like Particle / administration & dosage
-
Vaccines, Virus-Like Particle / immunology
Substances
-
Epitopes
-
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
-
Papillomavirus Vaccines
-
Vaccines, Virus-Like Particle